Population pharmacokinetics and pharmacodynamics of levofloxacin following intravenous infusion for respiratory tract infection

Medicine & Life Sciences

• Levofloxacin 100%
• Intravenous Infusions 79%
• Respiratory Tract Infections 76%
• Pharmacokinetics 61%
• Population 32%
• Intravenous Administration 17%
• Oral Administration 15%
• Streptococcus pneumoniae 9%
• Biological Availability 8%
• Volunteers 7%
• Creatinine 7%
• Body Weight 6%
• Elderly 6%